miR-4645-3p attenuates podocyte injury and mitochondrial dysfunction in diabetic kidney disease by targeting Cdk5

Yue Zhang1, Shunjie Xia2,3,4, Xiaoxi Tian2,3

  • 1Department of Diagnostics, Hebei Medical University, Shijiazhuang, China.

Insights

MicroRNA-4645-3p protects against diabetic kidney disease (DKD) by reducing podocyte injury and mitochondrial dysfunction. Restoring miR-4645-3p levels offers a potential therapeutic strategy for DKD.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Genetics

Background:

  • Podocyte injury is central to diabetic kidney disease (DKD) progression.
  • MicroRNAs (miRNAs) are implicated in kidney disease pathogenesis.
  • Mechanisms of podocyte injury in DKD require further elucidation.

Purpose of the Study:

  • To investigate the role of miR-4645-3p in diabetic kidney disease.
  • To identify the molecular targets and therapeutic potential of miR-4645-3p in DKD.

Main Methods:

  • Global transcriptome profiling identified downregulated miR-4645-3p in high glucose-induced podocytes.
  • In vitro studies used cultured podocytes under normal and high glucose conditions.
  • In vivo studies utilized streptozotocin-induced diabetic mouse models.
  • miR-4645-3p mimic and inhibitor transfections were performed.

Main Results:

  • miR-4645-3p expression was significantly decreased in DKD patients and diabetic mice.
  • Inhibition of miR-4645-3p promoted podocyte apoptosis and mitochondrial damage.
  • Overexpression of miR-4645-3p attenuated high glucose-induced podocyte injury and dysfunction.
  • miR-4645-3p directly targeted and inhibited Cyclin-dependent kinase 5 (Cdk5).
  • Exogenous miR-4645-3p treatment ameliorated podocyte injury, proteinuria, and renal dysfunction in vivo.

Conclusions:

  • miR-4645-3p acts as a protective factor against podocyte injury and mitochondrial dysfunction in DKD.
  • Targeting Cdk5 mediates the protective effects of miR-4645-3p.
  • Sustaining miR-4645-3p expression represents a potential novel therapeutic strategy for DKD.